Caring Brands, Inc. 是一家保健消費品公司,提供非處方藥及化妝品消費品。該公司總部位於佛羅里達州皮爾斯堡。
財務指標
營業收入
2026-09-30
--
2026-06-30
$0
2026-03-31
$0
2025-12-31
$420
營業支出
2026-09-30
$701.16K
2026-06-30
$638.73K
2026-03-31
$1.72M
2025-12-31
$3.73M
淨利潤
2026-09-30
-$827.05K
2026-06-30
-$638.72K
2026-03-31
-$2M
2025-12-31
-$4.06M
淨利潤率
2026-09-30
--
2026-06-30
--
2026-03-31
--
2025-12-31
-966.68K%
每股收益
2026-09-30
--
2026-06-30
$-0.10
2026-03-31
--
2025-12-31
--
息稅折舊攤銷前利潤
2026-09-30
--
2026-06-30
-$563.73K
2026-03-31
-$1.58M
2025-12-31
-$1.29M
有效稅率
2026-09-30
--
2026-06-30
--
2026-03-31
--
2025-12-31
--
項目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
營業收入
--
$0
$0
$420
營業支出
$701.16K
$638.73K
$1.72M
$3.73M
淨利潤
-$827.05K
-$638.72K
-$2M
-$4.06M
淨利潤率
--
--
--
-966.68K%
每股收益
--
$-0.10
--
--
息稅折舊攤銷前利潤
--
-$563.73K
-$1.58M
-$1.29M
有效稅率
--
--
--
--
常見問題
CABR stock represents shares of Cabaletta Bio, Inc., a clinical-stage biotechnology company. The ticker trades on the Nasdaq exchange. As a stock, it gives investors ownership exposure to the company's research and development programs, which are focused on engineered T cell therapies for autoimmune diseases. CABR does not currently market any approved products, so its value is tied primarily to clinical trial progress, cash position, and investor expectations for its pipeline rather than commercial sales.
Recent performance for CABR is shown in the price chart and performance data on this page. Clinical-stage biotech stocks like Cabaletta Bio can move sharply around trial updates, financing news, and sector sentiment, so recent returns may differ significantly from broader market averages. For the latest price change, percentage move, and period returns, refer to the current CABR quote and historical performance table displayed here.
Because Cabaletta Bio is a clinical-stage company with no product revenue, traditional valuation metrics such as the price-to-earnings ratio are generally not meaningful. Investors often focus on cash and cash equivalents, projected cash runway, enterprise value, and comparisons to peer biotechnology companies at similar stages of development. The valuation can also be influenced by the perceived probability of success for its pipeline candidates, potential market size, and dilution risk from future equity raises.
CABR can typically be bought through a brokerage account by placing a market or limit order during regular market hours. Investors should first confirm that their broker offers access to Nasdaq-listed stocks. Some brokers also allow extended-hours trading, though liquidity may be lower. Before trading, review the current bid-ask spread, trading volume, and any applicable commission or fee structure. Fractional shares may be available depending on the broker.
Key metrics for a clinical-stage biotech like Cabaletta Bio include cash and cash equivalents, quarterly operating expenses, net loss, and expected cash runway. Because CABR has no product revenue, investors also monitor research and development spending, general and administrative costs, and share count changes from financings. These figures come from quarterly and annual filings, such as 10-Q and 10-K reports. Clinical trial data and regulatory milestones are also central to the investment case.
Cabaletta Bio faces risks common to clinical-stage biotechnology companies, including the possibility that its T cell therapy candidates fail in clinical trials, delays in enrollment or regulatory review, competition from larger or faster-moving developers, and the need to raise additional capital, which can dilute existing shareholders. As a small-cap stock, CABR may also experience significant price volatility and lower liquidity than larger, more established companies. Changes in healthcare policy and reimbursement could further affect its prospects.